Lee NK, Skinner JP, Zajac JD, MacLean HE. Ornithine decarboxylase is upregulated by the androgen receptor in skeletal muscle and regulates myoblast proliferation. Am J Physiol Endocrinol Metab 301: E172-E179, 2011. First published April 19, 2011 doi:10.1152/ajpendo.00094.2011.-The aim of this study is to determine if the Odc1 gene, which encodes ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis, is directly regulated by the androgen receptor (AR) in skeletal muscle myoblasts and if Odc1 regulates myoblast proliferation and differentiation. We previously showed that expression of Odc1 is decreased in muscle from AR knockout male mice. In this study, we show in vivo that Odc1 expression is also decreased Ͼ60% in muscle from male muscle-specific AR knockout mice. In normal muscle homeostasis, Odc1 expression is regulated by age and sex, reflecting testosterone levels, as muscle of adult male mice expresses high levels of Odc1 compared with age-matched females and younger males. In vitro, expression of Odc1 is 10-and 1.5-fold higher in proliferating mouse C2C12 and human skeletal muscle myoblasts, respectively, than in differentiated myotubes. Dihydrotestosterone increases Odc1 levels 2.7-and 1.6-fold in skeletal muscle cell myoblasts after 12 and 24 h of treatment, respectively. Inhibition of ODC activity in C2C12 myoblasts by ␣-difluoromethylornithine decreases myoblast number by 40% and 66% following 48 and 72 h of treatment, respectively. In contrast, overexpression of Odc1 in C2C12 myoblasts results in a 27% increase in cell number vs. control when cells are grown under differentiation conditions for 96 h. This prolonged proliferation is associated with delayed differentiation, with reduced expression of the differentiation markers myogenin and Myf6 in Odc1-overexpressing cells. In conclusion, androgens act via the AR to upregulate Odc1 in skeletal muscle myoblasts, and Odc1 promotes myoblast proliferation and delays differentiation. knockout; anabolic; hypertrophy; polyamines; 5␣-dihydrotestosterone IN MALES, ANDROGENS ARE ESSENTIAL for the development and maintenance of reproductive tissues and secondary sexual characteristics (51). In addition, skeletal muscle is a major target for the anabolic actions of androgens, with androgens playing a role during normal muscle development, homeostasis, and adaptation; pharmacological effects are also observed. Androgens are required to achieve peak muscle mass in males during normal development, with a correlation between increasing levels of testosterone and muscle strength during adolescence (65) and a decrease in lean body mass in hypogonadal men (10). In addition, androgens can have anabolic actions in muscle in adult males, with clinical studies demonstrating a dose-dependent response of skeletal muscle to exogenously administered testosterone in young and elderly men, with increases in muscle size, strength, and fiber hypertrophy (12, 13). Testosterone treatment in hypogonadal men and human immunodeficiency virus-infected patients with muscle wasting also increases skeletal muscle mass (11, 16). Conversely, testosterone suppression in normal men or patients with prostate cancer causes a reduction in muscle size and strength (9, 48) . The latter data demonstrate that androgens not only induce muscle hypertrophy but that androgen withdrawal causes atrophy, indicating that physiological levels of androgens in adult men are required for normal muscle homeostasis.
IN MALES, ANDROGENS ARE ESSENTIAL for the development and maintenance of reproductive tissues and secondary sexual characteristics (51) . In addition, skeletal muscle is a major target for the anabolic actions of androgens, with androgens playing a role during normal muscle development, homeostasis, and adaptation; pharmacological effects are also observed. Androgens are required to achieve peak muscle mass in males during normal development, with a correlation between increasing levels of testosterone and muscle strength during adolescence (65) and a decrease in lean body mass in hypogonadal men (10) . In addition, androgens can have anabolic actions in muscle in adult males, with clinical studies demonstrating a dose-dependent response of skeletal muscle to exogenously administered testosterone in young and elderly men, with increases in muscle size, strength, and fiber hypertrophy (12, 13) . Testosterone treatment in hypogonadal men and human immunodeficiency virus-infected patients with muscle wasting also increases skeletal muscle mass (11, 16) . Conversely, testosterone suppression in normal men or patients with prostate cancer causes a reduction in muscle size and strength (9, 48) . The latter data demonstrate that androgens not only induce muscle hypertrophy but that androgen withdrawal causes atrophy, indicating that physiological levels of androgens in adult men are required for normal muscle homeostasis. Because serum testosterone levels decline with aging, this decline in testosterone has been proposed as one cause of age-related sarcopenia (36) . In addition, androgens play a role in adaptive responses of muscle. Changes in circulating or local testosterone and/or androgen receptor (AR) levels have been observed after exercise or overloading (5, 39, 70) , AR blockade can attenuate exercise-induced muscle hypertrophy (31, 37) , and some clinical studies in different patient cohorts show that the combination of androgen therapy and training increases muscle mass more than either intervention alone (19, 32, 63) . Despite the data from randomized controlled trials showing that androgens increase muscle mass and strength, androgens are not widely used therapeutically to increase muscle mass because of their potential side effects, including those on the reproductive and cardiovascular systems (67) . Therefore, gaining a better understanding of the mechanisms through which androgens increase skeletal muscle mass and strength is important for developing alternative therapies that eliminate undesirable side effects.
To mediate their effects in target tissues, androgens, including testosterone and 5␣-dihydrotestosterone (DHT), act via the AR. The ligand-bound AR regulates target gene expression via binding to specific androgen response elements (AREs) (44) . In addition to acting directly via the AR, testosterone can also be aromatized to estradiol to activate the estrogen receptor, and some actions of androgens in men, including in the brain, adipose tissue, and bone, are mediated via this pathway (4, 18, 33) . In contrast, DHT, which is derived from testosterone via 5␣-reduction, cannot be aromatized, and studies of men or mice lacking 5␣-reductase enzymes demonstrate that tissues including the prostate, seminal vesicles, and accessory sex glands require DHT for normal development (30, 46) . Although skeletal muscle exhibits significant aromatase activity (47) , the fact that 5␣-reductase deficiency or inhibition has no effect on muscle (15, 46) suggests that testosterone is the predominant androgen in skeletal muscle. Nonetheless, testosterone is likely to act predominantly via the AR in muscle, as treatment with the nonaromatizable DHT or selective AR modulators also induces anabolic responses in skeletal muscle (26, 27, 42) , and administration of AR antagonists, or deletion of the AR, reduces muscle mass (43, 56) . Increases in muscle mass can occur via two main mechanisms. 1) An increase in myonuclear number can occur via activation of satellite cells (muscle stem cells) into myoblasts, myoblast proliferation, differentiation into myotubes, and fusion with existing myofibers. 2) Postproliferative myofiber hypertrophy can arise through an increase in net protein content, with increased protein synthesis and/or decreased breakdown. All cell types within muscle express the AR, and it is likely that androgens act via both of these mechanisms in muscle (35) . We have used our global AR knockout (ARKO) mice (54) , which have an in-frame deletion of exon 3 of the AR gene that abolishes DNA binding (64) , to investigate AR-dependent actions in normal skeletal muscle development and function. The mass of various hindlimb muscles is reduced 15-22% and contractile strength is reduced in global ARKO mice (43) . We also identified a group of genes that is differentially expressed in ARKO male muscle, which included ornithine decarboxylase (Odc1). Expression of Odc1 was decreased by ϳ60% in global ARKO muscle (43) and was also reduced by 65% following orchidectomy of adult male mice (43) , suggesting that Odc1 is directly or indirectly regulated by the AR in skeletal muscle.
Odc1 encodes ODC, a rate-limiting enzyme in polyamine biosynthesis (2) . Polyamines (putrescine, spermidine, and spermine) play a crucial role in regulating gene expression, DNA and protein synthesis, and nucleic acid packaging, as well as cell proliferation and differentiation (38, 58) . Odc1 is essential for growth and development, as Odc1-null mouse embryos die at embryonic (E) day 5.5 (E5.5) (59) . Odc1 also mediates the proliferative actions of c-Myc in lymphomas, demonstrated by reduced B cell proliferation and delayed lymphoma development in heterozygous Odc1-knockout mice crossed with the E-Myc model of Myc-mediated tumorigenesis (53) . Thus Odc1 is a key regulator of cell proliferation in a number of systems, although its role in skeletal muscle is not known. In addition, Odc1 is directly regulated by the AR in kidney (28) , with a functional ARE identified in the promoter region (22) . We hypothesize that androgens have anabolic actions in skeletal muscle, in part via AR-dependent regulation of Odc1 expression, and that this pathway is regulated during normal muscle development and homeostatic function in males. Therefore, the aims of this study were 1) to determine the AR-dependent regulation of Odc1 in skeletal muscle using in vitro myoblast and in vivo ARKO mouse models; 2) to investigate the regulation of Odc1 in normal muscle homeostasis by determining if Odc1 is differentially expressed in sedentary male vs. female mice and embryonic, sexually immature, and adult mice; and 3) to characterize the function of Odc1 in regulating myoblast proliferation.
MATERIALS AND METHODS
Mice. To determine if Odc1 expression is regulated by age and/or sex, six groups of mice were analyzed (3ϫ age and 2ϫ sex). Wild-type (WT) male and female C57BL/6 mice were examined at E18.5 (embryonic; 10 male and 6 female), 4 wk of age (sexually immature; 6 male and 6 female), and 12 wk of age (adult; 9 male and 6 female). E18.5 mouse embryos were obtained by timed-mating, with the day of vaginal plug considered E0.5. To generate muscle-specific ARKO (mARKO) mice, we used our ␣-actin-Cre mouse line (34) and the muscle creatine kinase (MCK)-Cre line (17) (obtained from Ron Kahn, Joslin Diabetes Center) crossed with our exon 3 floxed AR mice (54) . All mice were on a congenic C57BL/6 background. The ␣-actin-Cre mice express Cre recombinase and have the AR deleted in proliferating myoblasts and myofibers, whereas the MCK-Cre mice express Cre recombinase and have the AR deleted only in postproliferative myofibers. mARKO males are hemizygous for the floxed AR allele on the X chromosome and heterozygous for the Cre transgene (AR fl/Y ;cre.Tg). ␣-Actin mARKO (n ϭ 13) and MCK mARKO (n ϭ 12) males were compared with WT male littermate controls (n ϭ 12-13/line) to investigate if Odc1 expression is regulated directly by the AR in skeletal muscle.
All mice were bred in-house, sedentary, housed in a conventional facility with a 12:12-h light-dark cycle, and allowed standard chow and water ad libitum. Studies were conducted in accordance with accepted standards of humane animal care and performed with the approval of the Austin Health Animal Ethics Committee. For gene expression studies, gastrocnemius muscle was harvested from sexually immature and adult mice as described previously (43) , and all hindlimb muscles were used from embryos to increase RNA yield.
Analysis of gene and protein expression. Quantitative real-time PCR (qPCR) was performed to measure gene expression in vivo and in vitro, as previously described (43), using the following Applied Biosystems expression assays: human Odc1 (assay ID Hs00159739_m1), mouse Odc1 [custom assay (43) ], mouse MyoD1 (assay ID Mm00440387_m1), myogenin (assay ID Mm00446194_m1), Myf5 (assay ID Mm00435125_m1), and Myf6 (assay ID Mm00435126_m1). Relative expression was determined using the cycle threshold (⌬⌬C T) method (40) , with expression normalized to ␤-actin (assay ID Mm00607939_s1) for the in vivo studies or 18S rRNA (assay ID 4310893E) for the in vitro studies, because ␤-actin expression is regulated by differentiation status in C2C12 cells in vitro (data not shown). For each experiment, data are expressed relative to one group for ease of comparison. Western blot analysis was performed to measure AR protein expression, as previously described (21), using the rabbit polyclonal anti-AR (PG-21, 1:400 dilution; Upstate) and mouse anti-␣-tubulin AA4.3 (1:1,000 dilution; Developmental Studies Hybridoma Bank) primary antibodies and the goat anti-mouse IgG-horseradish peroxidase (1:10,000 dilution) and goat anti-rabbit IgG-horseradish peroxidase (1:4,000 dilution; Santa Cruz Biotechnology) secondary antibodies. The same membrane was probed with anti-AR and anti-␣-tubulin antibodies, with the ␣-tubulin expression used to control for protein loading.
Cell culture. Two in vitro muscle cell lines were used to model myoblast and myotube functions, as mature multinucleated muscle fibers cannot be cultured over the long term in vitro. The C2C12 mouse myoblast cell line (kindly provided by George Muscat, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia) was maintained in proliferation medium comprising DMEM and 20% heat-inactivated FBS (GIBCO). The SkMC human skeletal muscle cell line (kindly provided by Peter Leedman, Western Australia Institute for Medical Research, Perth, Australia) was maintained in defined skeletal muscle cell growth medium with growth supplements (Lonza) containing 0.1% human epidermal growth factor, 1% insulin, and 0.1% dexamethasone. For proliferation experiments, cells were grown as myoblasts in their appropriate medium for up to 72 h. For differentiation experiments, proliferation medium was changed to DMEM with 3% horse serum (GIBCO) to induce differentiation into myotubes. To determine the expression of Odc1 during muscle cell proliferation and differentiation, C2C12 and SkMC cell lines were grown as myoblasts in proliferation medium for 48 h and then induced to differentiate into myotubes for 72 h. For androgen treatment studies, myoblasts were grown for 24 h in proliferation medium and treated with 10 nM DHT or vehicle (0.1% ethanol, n ϭ 6 -8/group) for 12 or 24 h.
To determine if ODC regulates proliferation, proliferating C2C12 myoblasts, which we previously used as a model of myoblast proliferation (21), were treated with difluoromethylornithine (DFMO; Chem-Impex), an irreversible and specific inhibitor of ODC. Myoblasts were seeded in proliferation medium for 1 h and then treated for 24, 48, or 72 h (n ϭ 4 -6/cell line), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed to measure myoblast number at each time point. To determine the concentration of DFMO that induces a half-maximal response (EC50), the BioDataFit program (Chang Bioscience, Castro Valley, CA) was utilized to calculate EC 50 from a sigmoidal dose-response curve using 1, 10, 100, 500, and 1,000 M DFMO. For single-dose inhibition experiments, cells were treated with 1 mM DFMO for 72 h and compared with vehicle (distilled H2O). All results were replicated from at least two independent experiments.
MTT assay. To determine cell number, MTT assays were performed by seeding 4,000 cells/cm 2 in 24-well tissue culture plates. At the indicated time points, 0.1 volume of MTT (5 mg/ml in PBS; Sigma Aldrich) was added to the wells, and the cells were incubated for 4 h at 37°C. After incubation, an equal volume of acidified SDS (10% SDS and 100 mM HCl) was added to cells to dissolve formazan crystals by incubation overnight at 37°C. Absorbance was measured at 570 nm on a microplate reader and corrected for the negative control (cell-free) background absorbance.
Stable transfections. C2C12 cells stably transfected with truncated ODC (pCMV-ODCT; kindly provided by Lisa Shantz, Department of Cellular and Molecular Physiology, Penn State Milton S. Hershey Medical Center) were generated as previously described (21) . The ODC protein is truncated by 37 amino acids by insertion of a termination codon at position 426, which results in ODC protein with a extended half-life (41) . Control cell lines were transfected with empty vector. Two independent cell lines for each of the control and Odc1-overexpressing C2C12 cells were studied in parallel, and data were pooled from the two cell lines for analysis.
Statistical analysis. For comparison of the mean of two groups, Levene's test was used to determine homogeneity of variance, and two-tailed unpaired Student's t-test was used for equal or unequal variance where appropriate. For comparison of the mean of more than two groups, one-or two-way ANOVA was used, and Tukey's post hoc test was used if Levene's test indicated equal variance, or Tamhane's post hoc test was used if Levene's test indicated unequal variance. SPSS version 17 was used for statistical analyses. P Ͻ 0.05 was considered significant.
RESULTS

Odc1 expression in muscle is regulated by sex, age, and AR.
We previously showed that Odc1 expression is reduced by 60% in gastrocnemius muscle from 9-wk-old global ARKO males compared with control males (43) . To investigate the regulation of Odc1 in normal muscle homeostasis, we used WT C57BL/6 mice to compare Odc1 expression in hindlimb muscle from males vs. females at E18.5, 4 wk of age (sexually immature), and 12 wk of age (adult) to determine if Odc1 is differentially expressed in relation to sex and age in muscle in vivo. Two-way ANOVA showed a significant effect of sex (P Ͻ 0.001) and age (P Ͻ 0.001) on Odc1 expression in muscle and an interaction between sex and age (P Ͻ 0.05). Male and female E18.5 embryos expressed low levels of Odc1 (Fig. 1A) , and Odc1 was upregulated in adult males, with high expression in 12-wk-old males compared with age-matched females (P Ͻ 0.05) and younger males (P Ͻ 0.05 vs. E18.5 and 4-wk-old males; Fig. 1A ). To determine if Odc1 is regulated by the AR specifically in skeletal muscle, we measured Odc1 levels in two mARKO mouse lines, the ␣-actin mARKO and MCK mARKO lines. The degree of AR deletion in both lines is similar in adult skeletal muscle, which comprises predominantly postproliferative myofibers, with AR mRNA expression reduced to 7% of WT in the ␣-actin mARKO mice and to 4% in the MCK mARKO mice (data not shown). In each line, Odc1 expression was expressed relative to expression in WT littermates, which was set at 100% for each line. Odc1 levels were decreased by 75% (P Ͻ 0.05) in muscle from ␣-actin mARKO males and 62% (P Ͻ 0.05) in muscle from MCK mARKO males compared with their respective WT littermate control males (Fig. 1B) , demonstrating a specific effect of AR deletion in skeletal muscle on Odc1 expression.
Odc1 is expressed predominantly in proliferating myoblasts and is regulated by DHT. To determine if Odc1 is differentially expressed during muscle cell proliferation and differentiation, we examined expression in two muscle cell lines: mouse C 2 C 12 and human SkMC. Direct comparisons of Odc1 expression levels could not be made between the two cell lines, since the C 2 C 12 cells are derived from mouse and SkMCs are human, so species-specific qPCR assays were used to detect Odc1 expression in each cell line. However, Odc1 was expressed at high levels during proliferation in both cell lines, with low expression in differentiated myotubes (Fig. 2) . Since the reduced Odc1 expression in mARKO mice suggested that the AR directly upregulates Odc1 expression in muscle (Fig. 1B) , the androgen responsiveness of Odc1 was also tested by treatment of proliferating SkMCs with the nonaromatizable androgen DHT to identify AR-mediated responses. SkMCs were used, because they had high AR mRNA and protein expression compared with C 2 C 12 cells (Fig. 3A; data not shown). In proliferating SkMC myoblasts, Odc1 expression was increased 2.7-fold in response to 12 h of DHT treatment (P Ͻ 0.05 vs. vehicle) and 1.6-fold after 24 h of DHT treatment (P Ͻ 0.05 vs. vehicle; Fig. 3B ), suggesting direct upregulation of Odc1 by the AR in myoblasts.
Inhibition of ODC decreases muscle cell proliferation. Since we showed that Odc1 is abundantly expressed in proliferating myoblasts and is known to regulate proliferation in other systems, using the highly specific inhibitor DFMO, we investigated the effect of ODC inhibition on C 2 C 12 myoblast proliferation. DFMO treatment reduced C 2 C 12 myoblast number by 40% at 48 h (P Ͻ 0.05 vs. vehicle) and 66% at 72 h (P Ͻ 0.001 vs. vehicle; Fig. 4) .
Overexpression of Odc1 increases muscle cell proliferation. Because inhibition of ODC significantly reduced C 2 C 12 myoblast proliferation, we determined if Odc1 overexpression could increase muscle cell proliferation. To overexpress Odc1, C 2 C 12 cells were stably transfected with murine Odc1 encoding a truncated, stabilized form of ODC (41) . Odc1 mRNA increased sevenfold in stably transfected cell lines compared with control cells [684 Ϯ 40.5 vs. 100 Ϯ 20.4 (SE), P Ͻ 0.05 vs. control, Student's t-test, n ϭ 2/group]. We measured cell number of control and Odc1-overexpressing C 2 C 12 myoblasts grown in proliferation medium (20% serum) for up to 72 h and found no difference in cell number (Fig. 5A) . However, when cells were grown under differentiation conditions (3% serum) for up to 96 h, control C 2 C 12 cells increased in number from 0 to 48 h ( Fig. 5B ; P Ͻ 0.001, 0 vs. 24 h; P Ͻ 0.05, 24 vs. 48 h) but stopped proliferating and showed no change in number from 48 to 96 h of differentiation. In contrast, the Odc1-overexpressing cells continued to increase in number at 96 h (P Ͻ 0.01, 48 vs. 96 h), resulting in a 27% increase in Odc1-overexpressing cells compared with the control cell lines at 96 h (P Ͻ 0.001 vs. control; Fig. 5B ).
To address whether Odc1 overexpression is able to compensate for the reduction in myoblast proliferation caused by ODC inhibition by DFMO, we treated control C 2 C 12 and Odc1-overexpressing cells with a range of DFMO concentrations for 72 h and measured cell number to determine the EC 50 for DFMO (Fig. 5C ). For the control cells, 10 M DFMO was sufficient to reduce cell number by 30% compared with vehicle (P Ͻ 0.05), and the maximal effect was observed at 1 mM (P Ͻ 0.001); for the Odc1-overexpressing cells, there was no significant effect of 10 M DFMO compared with vehicle, but the maximal effect was still observed at 1 mM (P Ͻ 0.05). However, at each concentration of DFMO, there was no significant difference in number between control and Odc1-overexpressing cells (Fig. 5C) , and there was no difference in EC 50 between the cell lines (data not shown). This demon- strates that although the overexpression of Odc1 in transfected C 2 C 12 cells was sufficient to increase cell number when cells were grown under differentiation conditions, it was not able to reverse the reduction in myoblast proliferation caused by inhibition of ODC activity.
To determine the effect of Odc1 overexpression at the molecular level, we analyzed the expression of the myogenic regulatory factors at 96 h postdifferentiation, the time point at which cell number was increased compared with control. Control C 2 C 12 and Odc1-overexpressing cells showed no difference in expression levels of MyoD1 and Myf5 (Fig. 5D ), which are highly expressed during myoblast proliferation (73) . However, myogenin expression decreased 57% (P Ͻ 0.05) and Myf6 expression decreased 42% (P Ͻ 0.05) in Odc1-overexpressing cells compared with control cells (Fig. 5D) , consistent with the hypothesis that Odc1-overexpressing cells are continuing to proliferate as myoblasts.
DISCUSSION
Our findings demonstrate that Odc1 expression is regulated by age and sex in skeletal muscle, with expression high in muscle from 12-wk-old adult male mice compared with adult female and younger male mice. High Odc1 expression in male muscle requires the AR in skeletal muscle, with reduced Odc1 expression in ␣-actin mARKO and MCK mARKO compared with control males. In human and mouse myoblast cell lines (SkMC and C 2 C 12 ), Odc1 is highly expressed in proliferating myoblasts compared with differentiated myotubes, suggesting a role in proliferation, and DHT treatment increases Odc1 expression. The significance of Odc1 for myoblast proliferation is demonstrated by the fact that enzymatic inhibition of ODC by DFMO reduces myoblast number by Ͼ60%. In addition, overexpression of Odc1 increases myoblast number when cells are grown under differentiation conditions, and at the same time there is a reduction in the expression of myogenin and Myf6, markers of differentiation. These data demonstrate that Odc1 is directly regulated by the AR in skeletal muscle myoblasts and that ODC promotes myoblast proliferation and delays differentiation.
Previous studies have shown that Odc1 is directly regulated by androgens in mouse kidney (22) and reproductive tissues (22, 60) . Similarly, we previously demonstrated that Odc1 is regulated by androgens directly or indirectly via the AR in skeletal muscle, evidenced by decreased levels of Odc1 in muscle from global ARKO and orchidectomized male mice (43), both of which have reduced muscle mass (3, 43) . To determine if Odc1 is specifically regulated by the AR in skeletal muscle, we examined expression in two mARKO mouse lines. The fact that Odc1 expression is also decreased in muscle from both of these mARKO lines demonstrates that Odc1 is regulated by the AR directly in skeletal muscle. To identify the target cell in which Odc1 is expressed in muscle, we used C 2 C 12 and SkMC myoblast cell lines to show that expression of Odc1 is high in proliferating myoblasts and is reduced following differentiation into myotubes. In addition, Odc1 expression is further increased by treatment of myoblasts with DHT, which is nonaromatizable and, therefore, can only act via the AR. Taken together with the previous identification of an ARE in the Odc1 gene promoter (22) , these data demonstrate that androgens act directly through the AR to upregulate Odc1 expression in skeletal muscle myoblasts.
Our results from the current study and our previous analysis of global ARKOs and orchidectomized WT mice (43) show that Odc1 is regulated by the AR and androgens in genetically and surgically modified mouse models. While results from the ARKO model reflect the regulation of Odc1 during muscle development, results from the orchidectomy study show the Odc1 regulation in the context of androgen withdrawal-dependent muscle atrophy and remodeling. It was also important to determine if expression of Odc1 is regulated in normal muscle homeostasis. Therefore, we compared expression in WT males with that in females, as we hypothesized that if the Odc1 gene is regulated by physiological levels of androgens, expression will be higher in adult males than adult females. The fact that Odc1 expression is high in muscle from 12-wk-old males compared with age-matched females supports this hypothesis and suggests that this differential expression may contribute to the greater muscle mass in adult males than females (43) . Within each sex, we also examined the effect of age on Odc1 expression in muscles from embryonic (E18.5), sexually immature (4 wk old), and mature adult (12 wk old) mice, as it has previously been demonstrated that serum testosterone levels in male mice are low before 25 days of age and reach a maximum at 60 days of age (8) . In males, the higher expression in adult muscle than in younger sex-matched counterparts is consistent with the previously reported rise in testosterone levels to maximum in adult males (8) and demonstrates that Odc1 is upregulated during normal muscle development in males. To a lesser degree, Odc1 is also increased in adult females compared with younger females, which may also be an androgen/ AR-mediated effect in females, as it has been shown that adult females have higher androgen levels than sexually immature females, because the mature ovary synthesizes androgens during folliculogenesis (72) .
The importance of ODC in regulating cell proliferation and survival has been reported in a number of other systems, including Caenorhabditis elegans (45) , and mouse embryonic development (59) and in tumor models, including skin cancers (25, 55) and lymphomas (53) . However, its role in skeletal muscle has not been examined. We showed that ODC regulates myoblast proliferation, by the fact that inhibition of ODC activity by DFMO reduces C 2 C 12 myoblast number by Ͼ60% during proliferation. DFMO is a highly specific inhibitor of ODC activity (62) , and while our initial studies used a relatively high DFMO concentration (1 mM) to inhibit ODC completely (Fig. 4) , we also demonstrated that DFMO concentrations as low as 10 M were sufficient to reduce cell number by 30% (Fig. 5C ), which strongly suggests that this is a specific effect of ODC inhibition, rather than a toxic effect of DFMO. Despite the importance of ODC for myoblast proliferation, Odc1 overexpression is not able to increase myoblast number under proliferation conditions. This may be because cell lines have been selected to proliferate in culture, and thus growth rate may already be maximal under normal proliferation culture conditions. This view is supported by the fact that Odc1 overexpression results in an increased number of myoblasts when cells are cultured under differentiation (low serum) conditions, showing that an increase in proliferation rate is detectable in low-growth conditions. This increase in cell number is observed 96 h following induction of differentiation, a time point at which we showed that control C 2 C 12 cells stopped proliferating (no change in cell number) and differentiated into myotubes (21) . In addition, there is a decrease in expression of myogenin and Myf6 in Odc1-overexpressing cells compared with control cells at this time point. Myogenin and Myf6 belong to the family of conserved basic helix-loop-helix myogenic regulatory factors that control muscle development in vertebrates (75) . Myogenin and Myf6 are required for terminal differentiation of myoblasts into myotubes and fusion into multinucleate myofibers and are highly expressed in myotubes (29, 52, 57, 66) . Therefore, these data suggest that, despite the increased number of cells following Odc1 overexpression, there are fewer differentiated myotubes but more proliferative myoblasts as a result of delayed differentiation. This result is consistent with a study showing that nandrolone decanoate treatment decreased myogenin levels in functionally overloaded rat muscle (49) and suggests a mechanism for increasing muscle mass by prolonging myoblast proliferation and delaying differentiation to increase total myocyte number.
Consistent with the finding that Odc1 overexpression does not increase myoblast number under proliferation conditions (Fig. 5A) , it also does not reverse the reduction in myoblast number caused by DFMO (Fig. 5C) , with control and Odc1-overexpressing cells having similar EC 50 values. This is most likely because the increase in Odc1 expression may not have been sufficient to rescue myoblast proliferation when the cells were treated with DFMO, which is a powerful and irreversible inhibitor of ODC activity (62) .
Our data strongly suggest that androgens act through the AR in skeletal muscle to increase Odc1 expression and that this results in increased myoblast proliferation. However, we have been unable to show a direct effect of androgens to increase C 2 C 12 or SkMC proliferation rate in vitro (21) (data not shown). This may be because cells express very low or undetectable levels of AR (21) or because of the previously discussed difficulty in identifying the effects of factors that upregulate proliferation in cell lines that have been selected for growth in vitro. Nonetheless, other studies have demonstrated that androgens can increase myoblast proliferation or delay differentiation, including increasing the number of C 2 C 12 myoblasts in the S phase (23) , increasing the proliferation rate of L6 myoblasts (61) , increasing the proliferation of myoblasts (activated satellite cells) in muscle from older men following 20 wk of androgen treatment (69) , and delaying the differentiation of porcine myoblasts into myotubes (24) . Therefore, we propose that the anabolic actions of androgens in skeletal muscle occur in part through this AR-Odc1 pathway to upregulate myoblast proliferation and delay differentiation, resulting in increased number of myonuclei and increasing muscle mass. This proposed role of ODC in muscle is further supported by a number of studies showing that other factors that induce muscle hypertrophy, including exercise and ␤-adrenergic agonists, also increase polyamine levels or expression of polyamine regulatory genes (1, 7, 20, 71, 74) . The definitive evidence that Odc1 mediates the anabolic actions of androgens in skeletal muscle would be to show that overexpression of Odc1 in skeletal muscle rescues the reduced muscle mass in ARKO male mice (43) .
In conclusion, we have shown that androgens act via the AR to regulate Odc1 expression in skeletal muscle myoblasts and that ODC regulates myoblast proliferation, suggesting that androgens may have anabolic actions in muscle via ARdependent upregulation of Odc1. This fact also raises the possibility that ODC may be a useful therapeutic target to increase muscle mass. ODC is already a therapeutic target for hirsutism in women, with topical inhibition slowing androgendependent hair growth in the hair follicle (14) . Our data suggest that developing small-molecule ODC agonists to specifically target skeletal muscle could increase muscle mass without the negative side effects of current androgen treatments. Such therapies would be valuable to increase muscle mass in conditions associated with decreased muscle mass, including human immunodeficiency virus (50), cancer cachexia (6), and sarcopenia (68) .
